Team/Members of the group:
Cancer Immunology and Immunotherapy Group 

• Andrew Sheppard PhD student
• Maria Davern PhD student
• Dr Cliona Lorton PhD student
• Dr Noel Donlon PhD student
• Ms Rebecca O’Brien PhD student (Co-supervisor)
• Ms Eimear Mylod PhD student (co-supervisor) 
• Ms Adele Connor (Co-supervisor; UCD) 
• Ms Rebecca Lyons PhD student
• Dr Brendan Moran PhD student (RSCI/SJH/TCD)
• Dr Deborah Gavin (MD student

Close collaborators:

• Prof. John V. Reynolds (SJH/TCD/TSJCI)
• Prof. Jacintha O’Sullivan (TCD/TSJCI)
• Dr Stephen Maher (TCD/TSJCI)
• Dr Niamh Lynam-Lennon (TCD/TSJCI)
• Dr Melissa Conroy (TCD/TSJCI)
• Prof. Maeve Lowery (TCD/SJH/TSJCI)
• Prof. Connail McCrory (SJH)
• Dr Claire Donohoe (SJH/TCD/TSJCI)
• Prof. Clair Gardiner (TCD/TSJCI)
• Dr Aideen Ryan (NUIG)
• Dr Elizabeth Ryan (UL)
• Dr Derek Doherty (TCD/TSJCI)
• Dr Jarushka Naidoo (RCSI/Beaumont)
• Prof. Juliette Hussey (TCD/TSCJI)
• Dr Peter Beddy (SJH)
• Dr Michael Quante (TUM, Germany)
• Prof. Declan Walsh (Levine Cancer Institute, USA)

Main Funders:
Health Research Board, Science Foundation Ireland, Irish Research Council, Breakthrough Cancer Research, Irish Cancer Society, CROSS Cancer Research   

Active research programmes: 
Dr Lysaght's research group focuses on a number of different areas around the central theme of T cells in cancer immunology and immunotherapy. The majority of research is focused on upper gastrointestinal cancer, particularly oesophageal, gastric and pancreatic cancer. Currently, a major research focus of the group is investigating the impact and scheduling of combination chemotherapy/radiotherapy with immunotherapy (immune checkpoint inhibitors). We are also investigating the immune-independent effects of immune checkpoint inhibitors. The crucial role of the tumour microenvironment and immunometabolism on anti-tumour T cell responses is also a central research focus of the group. Research into how the regulation and trafficking of lymphocytes (T and NK cells) can be targeted as a cancer therapeutic is also being investigated. Other areas of interest include identifying novel immunotherapeutic targets in the pre-malignant setting such as Barrett's Oesophagus, which can be used to slow or prevent progression to malignancy. The group is also actively researching obesity and cancer, and how this impacts hepatic and adipose tissue inflammation, anti-tumour immunity and cancer-associated cachexia and sarcopenia.